drugset / Trial / NCT03961568
Cenobamate Open-Label Extension Study for YKP3089C025
Non-randomizedSingle-groupOpen-labelTreatment
Summary
52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)
Timeline
- Start
- 2019-08-13
- Primary completion
- 2026-06-10
- Completion
- 2026-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cenobamate | Small molecule | 50 mg | Oral |
| Subject | Cenobamate | Small molecule | 150 mg | Oral |
| Subject | Cenobamate | Small molecule | 200 mg | Oral |